These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 24320998)

  • 21. Design of small-molecule peptidic and nonpeptidic Smac mimetics.
    Sun H; Nikolovska-Coleska Z; Yang CY; Qian D; Lu J; Qiu S; Bai L; Peng Y; Cai Q; Wang S
    Acc Chem Res; 2008 Oct; 41(10):1264-77. PubMed ID: 18937395
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.
    Allensworth JL; Sauer SJ; Lyerly HK; Morse MA; Devi GR
    Breast Cancer Res Treat; 2013 Jan; 137(2):359-71. PubMed ID: 23225169
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of Potent SMAC Mimetics that Sensitize Cancer Cells to TNF Family-Induced Apoptosis.
    Welsh K; Milutinovic S; Ardecky RJ; Gonzalez-Lopez M; Ganji SR; Teriete P; Finlay D; Riedl S; Matsuzawa S; Pinilla C; Houghten R; Vuori K; Reed JC; Cosford ND
    PLoS One; 2016; 11(9):e0161952. PubMed ID: 27617834
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potent bivalent Smac mimetics: effect of the linker on binding to inhibitor of apoptosis proteins (IAPs) and anticancer activity.
    Sun H; Liu L; Lu J; Bai L; Li X; Nikolovska-Coleska Z; McEachern D; Yang CY; Qiu S; Yi H; Sun D; Wang S
    J Med Chem; 2011 May; 54(9):3306-18. PubMed ID: 21462933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design and synthesis of potent inhibitor of apoptosis (IAP) proteins antagonists bearing an octahydropyrrolo[1,2-a]pyrazine scaffold as a novel proline mimetic.
    Hashimoto K; Saito B; Miyamoto N; Oguro Y; Tomita D; Shiokawa Z; Asano M; Kakei H; Taya N; Kawasaki M; Sumi H; Yabuki M; Iwai K; Yoshida S; Yoshimatsu M; Aoyama K; Kosugi Y; Kojima T; Morishita N; Dougan DR; Snell GP; Imamura S; Ishikawa T
    J Med Chem; 2013 Feb; 56(3):1228-46. PubMed ID: 23298277
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Discovery of a Non-Alanine Lead Series with Dual Activity Against cIAP1 and XIAP.
    Chessari G; Buck IM; Day JE; Day PJ; Iqbal A; Johnson CN; Lewis EJ; Martins V; Miller D; Reader M; Rees DC; Rich SJ; Tamanini E; Vitorino M; Ward GA; Williams PA; Williams G; Wilsher NE; Woolford AJ
    J Med Chem; 2015 Aug; 58(16):6574-88. PubMed ID: 26218264
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of aminopiperidine-based Smac mimetics as IAP antagonists.
    Hennessy EJ; Saeh JC; Sha L; MacIntyre T; Wang H; Larsen NA; Aquila BM; Ferguson AD; Laing NM; Omer CA
    Bioorg Med Chem Lett; 2012 Feb; 22(4):1690-4. PubMed ID: 22264476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer.
    Oost TK; Sun C; Armstrong RC; Al-Assaad AS; Betz SF; Deckwerth TL; Ding H; Elmore SW; Meadows RP; Olejniczak ET; Oleksijew A; Oltersdorf T; Rosenberg SH; Shoemaker AR; Tomaselli KJ; Zou H; Fesik SW
    J Med Chem; 2004 Aug; 47(18):4417-26. PubMed ID: 15317454
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacology of smac mimetics; chemotype differentiation based on physical association with caspase regulators and cellular transport.
    Talbott RL; Borzilleri RM; Chaudhry C; Fargnoli J; Shen H; Fairchild C; Barnhart B; Ortega M; McDonagh TE; Vuppugalla R; Vite GD; Hunt JT; Gottardis M; Naglich JG
    Exp Cell Res; 2015 Nov; 338(2):251-60. PubMed ID: 26302264
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IAP Proteins Antagonist: An Introduction and Chemistry of Smac Mimetics under Clinical Development.
    Ali R; Singh S; Haq W
    Curr Med Chem; 2018; 25(31):3768-3795. PubMed ID: 29532750
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis, biological evaluation and molecular modeling studies of 1-aryl-6-(3,4,5-trimethoxyphenyl)-3(Z)-hexen-1,5-diynes as a new class of potent antitumor agents.
    Lo YH; Lin YT; Liu YP; Duh TH; Lu PJ; Wu MJ
    Eur J Med Chem; 2013 Apr; 62():526-33. PubMed ID: 23419737
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structural basis for bivalent Smac-mimetics recognition in the IAP protein family.
    Cossu F; Milani M; Mastrangelo E; Vachette P; Servida F; Lecis D; Canevari G; Delia D; Drago C; Rizzo V; Manzoni L; Seneci P; Scolastico C; Bolognesi M
    J Mol Biol; 2009 Sep; 392(3):630-44. PubMed ID: 19393243
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bivalent SMAC Mimetics for Treating Cancer by Antagonizing Inhibitor of Apoptosis Proteins.
    Zhu H; Li Y; Liu Y; Han B
    ChemMedChem; 2019 Dec; 14(23):1951-1962. PubMed ID: 31692274
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cyclopeptide Smac mimetics as antagonists of IAP proteins.
    Sun H; Liu L; Lu J; Qiu S; Yang CY; Yi H; Wang S
    Bioorg Med Chem Lett; 2010 May; 20(10):3043-6. PubMed ID: 20443226
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Simultaneous XIAP and cIAP1/2 inhibition by a dimeric SMAC mimetic AZD5582 induces apoptosis in multiple myeloma.
    Kikuchi S; Sugama Y; Takada K; Kamihara Y; Wada A; Arihara Y; Nakamura H; Sato T
    J Pharmacol Sci; 2024 Jan; 154(1):30-36. PubMed ID: 38081681
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure-based design and synthesis of tricyclic IAP (Inhibitors of Apoptosis Proteins) inhibitors.
    Hird AW; Aquila BM; Block MH; Hennessy EJ; Kamhi VM; Omer CA; Laing NM; Saeh JC; Sha L; Yang B
    Bioorg Med Chem Lett; 2014 Apr; 24(7):1820-4. PubMed ID: 24631189
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models.
    Benetatos CA; Mitsuuchi Y; Burns JM; Neiman EM; Condon SM; Yu G; Seipel ME; Kapoor GS; Laporte MG; Rippin SR; Deng Y; Hendi MS; Tirunahari PK; Lee YH; Haimowitz T; Alexander MD; Graham MA; Weng D; Shi Y; McKinlay MA; Chunduru SK
    Mol Cancer Ther; 2014 Apr; 13(4):867-79. PubMed ID: 24563541
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design and characterization of bivalent Smac-based peptides as antagonists of XIAP and development and validation of a fluorescence polarization assay for XIAP containing both BIR2 and BIR3 domains.
    Nikolovska-Coleska Z; Meagher JL; Jiang S; Kawamoto SA; Gao W; Yi H; Qin D; Roller PP; Stuckey JA; Wang S
    Anal Biochem; 2008 Mar; 374(1):87-98. PubMed ID: 18023397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rational design, synthesis and characterization of potent, drug-like monomeric Smac mimetics as pro-apoptotic anticancer agents.
    Bianchi A; Ugazzi M; Ferrante L; Lecis D; Scavullo C; Mastrangelo E; Seneci P
    Bioorg Med Chem Lett; 2012 Mar; 22(6):2204-8. PubMed ID: 22342627
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nonpeptidic and potent small-molecule inhibitors of cIAP-1/2 and XIAP proteins.
    Sun H; Lu J; Liu L; Yi H; Qiu S; Yang CY; Deschamps JR; Wang S
    J Med Chem; 2010 Sep; 53(17):6361-7. PubMed ID: 20684551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.